An Overview of RNF39: A Potential Drug Target and Biomarker (G80352)

Target Name: RNF39

NCBI ID: G80352

RNF39

An Overview of RNF39: A Potential Drug Target and Biomarker

Abstract:
RNA-Nucleic Acid (RNA) folding is a fundamental process that occurs in all living cells, plays a crucial role in gene expression, and is implicated in various diseases. The nuclear receptor RNA-Nucleic Acid (RNF39) gene, located on chromosome 21, encodes a protein named NF-Y6, which is a key regulator of RNA-folding. The RNA-folding defect in NF-Y6 has been implicated in various human diseases, including cancer, neurodegenerative diseases, and developmental disorders. The identification of RNA-folding regulators, such as RNF39, provides new avenues for drug development and biomarker research.

Introduction:
Nucleic acid folding is the process by which RNA secondary structures are formed from a primary structure. These structures, such as alphahelices and betahelices, play important roles in regulating gene expression and are implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The nuclear receptor RNA-Nucleic Acid (RNF39) gene, located on chromosome 21, encodes a protein named NF-Y6, which is a key regulator of RNA-folding. The RNA-folding defect in NF-Y6 has been implicated in various human diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The Importance of RNA-Folding:
RNA-folding is a critical process in the regulation of gene expression and has been implicated in various diseases. The formation of secondary structures, such as alphahelices and betahelices, play important roles in regulating gene expression and have been implicated in the development of cancer, neurodegenerative diseases, and developmental disorders. In addition, RNA-folding is also important for the regulation of cellular processes, including cell signaling, DNA replication, and repair.

The Identification of RNA-Folding Regulators:
The identification of RNA-folding regulators is an important area of research, as these regulators can provide new avenues for drug development and biomarker research. The nuclear receptor RNA-Nucleic Acid (RNF39) gene, located on chromosome 21, encodes a protein named NF-Y6, which is a key regulator of RNA-folding. The RNA-folding defect in NF-Y6 has been implicated in various human diseases, including cancer, neurodegenerative diseases, and developmental disorders.

The Structure and Function of RNF39:
The RNA-Nucleic Acid (RNF39) gene encodes a protein named NF-Y6, which is a 21-kDa protein that contains 115 amino acid residues. The protein has a characteristic Rossmann-fold, which is a type of hydrogen bonding that forms when the nitrogenous residues in a molecule bind to a carbon atom that has a double bond. The Rossmann-fold is responsible for the stability and stability of the protein and is a key factor in its function.

The Role of RNF39 in RNA-Folding:
The RNA-Nucleic Acid (RNF39) gene encodes a protein named NF-Y6, which is a key regulator of RNA-folding. The NF-Y6 protein has been shown to play a crucial role in the regulation of RNA-folding and has been implicated in various human diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Drug Development and Biomarker Research:
The identification of RNA-folding regulators, such as RNF39, provides new avenues for drug development and biomarker research. The development of small molecules that can modulate the activity of RNF39 and improve the regulation of RNA-folding could lead to new treatments for various human diseases. In addition, the study of RNA-folding

Protein Name: Ring Finger Protein 39

Functions: May play a role in prolonged long term-potentiation (LTP) maintenance

The "RNF39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets